Coronavirus (COVID-19) Collection
Critically ill patients with COVID-19 show lung fungal dysbiosis with reduced microbial diversity in patients colonized with Candida spp.
Coronaviruses are important human and animal pathogens. At the end of 2019, a novel coronavirus was identified as the causative agent of a pneumonia outbreak in Wuhan, China, that subsequently spread worldwide in a global pandemic. Globally, there have been more than 240 million confirmed cases of COVID-19, including nearly 5 million deaths ( https://www.who.int/ ). Critically ill patients with COVID-19 may develop acute respiratory distress syndrome (ARDS), requiring admission in intensive care unit (ICU) and mechanical ventilation, which predisposes them to bacterial and fungal superinfections (Bassetti et al., 2020; Lansbury et al., 2020; Chong et al., 2021).Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19
The deleterious impact of the hyperactive immune response triggered by SARS-CoV-2 has been reported since the start of the pandemic (Giamarellos-Bourboulis et al., 2020, Vabret et al., 2020). Therapeutic immunomodulation emerged as a potentially life-saving option for patients with severe COVID-19 (Luis et al., 2021). Available drugs inhibiting the pleiotropic proinflammatory cytokine interleukin 6 (IL-6) rapidly became of particular interest because elevated IL-6 levels seemed to mediate systemic inflammatory responses associated with SARS-CoV-2 infection and the development of acute respiratory distress syndrome (ARDS) and multiorgan failure (McGonagle et al., 2020).Patients with COVID-19 pneumonia with 25(OH)D levels lower than 12 ng/ml are at increased risk of death
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses the angiotensin-converting enzyme 2 (ACE2) receptor to enter macrophages and monocytes, resulting in macrophage activation (Merad, Martin, 2020). In some patients, this leads to a hyperinflammatory syndrome, acute respiratory distress syndrome (ARDS), and end-organ damage (Webb et al., 2020). It has been hypothesized that vitamin D sufficiency may modulate this excessive inflammatory response in coronavirus disease 2019 (COVID-19) (Grant et al., 2020).Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry
Since the beginning of 2020, the world has faced the coronavirus disease 2019 (COVID-19) pandemic. As of November 11, 2021, more than 250 million people had contracted COVID-19 worldwide, and more than 5 million had died (Dong et al., 2020).Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study
The novel coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has exerted enormous relentless pressures on the global healthcare systems. As of February 4, 2021, over 102 million people were infected with SARS-CoV-2, and more than 2.2 million have died since the start of the pandemic (WHO, 2020). The true number of cases may even exceed the number of diagnosed cases by more than 10-fold (Havers et al., 2020; Stringhini et al., 2020).Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale
Acute cor pulmonale (ACP) is characterized by an unexpected rise in pulmonary vascular resistance and is closely associated with acute respiratory distress syndrome (ARDS) (Jardin and Vieillard-Baron, 2009; Biswas, 2016). We have all witnessed the pandemic spread of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; research has shown that some patients suffering from this disease (coronavirus disease 2019; COVID-19) have developed ARDS (Wang et al., 2020). Interestingly, Creel-Bulos et al.Oxygen metabolism markers as predictors of mortality in severe COVID-19
Recently, the medical world has focused its attention on the diagnosis and treatment of coronavirus disease 2019 (COVID-19) (Coronavirus (COVID-19), 2020). The number of cases of COVID-10 and the number of associated deaths are increasing daily. Due to the significant number of deaths, prediction of the outcome of COVID-19 is essential, and there is a need to identify predictive markers of mortality for infected patients. This was the subject of a recent meta-analysis by Tian et al. (2020), who reported that levels of cardiac troponin, C-reactive protein (CRP), interleukin-6, D-dimer, creatinine, alanine transferase and albumin can be used to predict mortality in patients with COVID-19.
